Coeptis Therapeutics, Inc.
COEP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $237 | $201 | $63 | $0 |
| % Growth | 18.3% | 219.2% | – | – |
| Cost of Goods Sold | $45 | $45 | $45 | $260 |
| Gross Profit | $192 | $156 | $18 | -$260 |
| % Margin | 81% | 77.5% | 28.2% | – |
| R&D Expenses | $587 | $290 | $87 | $344 |
| G&A Expenses | $201 | $4,136 | $269 | $0 |
| SG&A Expenses | $201 | $4,136 | $376 | $1,558 |
| Sales & Mktg Exp. | $0 | $0 | $107 | $0 |
| Other Operating Expenses | $1,881 | $250 | $3,612 | $0 |
| Operating Expenses | $2,669 | $4,677 | $4,075 | $1,902 |
| Operating Income | -$2,477 | -$4,521 | -$4,057 | -$2,162 |
| % Margin | -1,043.2% | -2,252.9% | -6,452.6% | – |
| Other Income/Exp. Net | -$422 | $187 | $636 | -$850 |
| Pre-Tax Income | -$2,899 | -$4,335 | -$3,421 | -$3,012 |
| Tax Expense | -$2,739 | $0 | $0 | $0 |
| Net Income | -$159 | -$3,535 | -$3,058 | -$3,012 |
| % Margin | -67.1% | -1,761.3% | -4,863.3% | – |
| EPS | -0.58 | -0.95 | -0.99 | 4.09 |
| % Growth | 38.9% | 4% | -124.2% | – |
| EPS Diluted | -0.58 | -0.95 | -0.99 | 4.09 |
| Weighted Avg Shares Out | 4,745 | 3,707 | 3,073 | 1,925 |
| Weighted Avg Shares Out Dil | 4,745 | 3,707 | 3,073 | 1,925 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $63 | $68 | $71 | $79 |
| Depreciation & Amortization | $306 | $306 | $305 | $260 |
| EBITDA | -$2,530 | -$3,961 | -$3,044 | -$2,673 |
| % Margin | -1,065.7% | -1,973.9% | -4,841.7% | – |